Cargando…

Diversity of immune checkpoints in cancer immunotherapy

Finding effective treatments for cancer remains a challenge. Recent studies have found that the mechanisms of tumor evasion are becoming increasingly diverse, including abnormal expression of immune checkpoint molecules on different immune cells, in particular T cells, natural killer cells, macropha...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Zhangyan, Zhang, Rui, Yang, An-Gang, Zheng, Guoxu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027905/
https://www.ncbi.nlm.nih.gov/pubmed/36960057
http://dx.doi.org/10.3389/fimmu.2023.1121285
_version_ 1784909815726735360
author Guo, Zhangyan
Zhang, Rui
Yang, An-Gang
Zheng, Guoxu
author_facet Guo, Zhangyan
Zhang, Rui
Yang, An-Gang
Zheng, Guoxu
author_sort Guo, Zhangyan
collection PubMed
description Finding effective treatments for cancer remains a challenge. Recent studies have found that the mechanisms of tumor evasion are becoming increasingly diverse, including abnormal expression of immune checkpoint molecules on different immune cells, in particular T cells, natural killer cells, macrophages and others. In this review, we discuss the checkpoint molecules with enhanced expression on these lymphocytes and their consequences on immune effector functions. Dissecting the diverse roles of immune checkpoints in different immune cells is crucial for a full understanding of immunotherapy using checkpoint inhibitors.
format Online
Article
Text
id pubmed-10027905
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100279052023-03-22 Diversity of immune checkpoints in cancer immunotherapy Guo, Zhangyan Zhang, Rui Yang, An-Gang Zheng, Guoxu Front Immunol Immunology Finding effective treatments for cancer remains a challenge. Recent studies have found that the mechanisms of tumor evasion are becoming increasingly diverse, including abnormal expression of immune checkpoint molecules on different immune cells, in particular T cells, natural killer cells, macrophages and others. In this review, we discuss the checkpoint molecules with enhanced expression on these lymphocytes and their consequences on immune effector functions. Dissecting the diverse roles of immune checkpoints in different immune cells is crucial for a full understanding of immunotherapy using checkpoint inhibitors. Frontiers Media S.A. 2023-03-07 /pmc/articles/PMC10027905/ /pubmed/36960057 http://dx.doi.org/10.3389/fimmu.2023.1121285 Text en Copyright © 2023 Guo, Zhang, Yang and Zheng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Guo, Zhangyan
Zhang, Rui
Yang, An-Gang
Zheng, Guoxu
Diversity of immune checkpoints in cancer immunotherapy
title Diversity of immune checkpoints in cancer immunotherapy
title_full Diversity of immune checkpoints in cancer immunotherapy
title_fullStr Diversity of immune checkpoints in cancer immunotherapy
title_full_unstemmed Diversity of immune checkpoints in cancer immunotherapy
title_short Diversity of immune checkpoints in cancer immunotherapy
title_sort diversity of immune checkpoints in cancer immunotherapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027905/
https://www.ncbi.nlm.nih.gov/pubmed/36960057
http://dx.doi.org/10.3389/fimmu.2023.1121285
work_keys_str_mv AT guozhangyan diversityofimmunecheckpointsincancerimmunotherapy
AT zhangrui diversityofimmunecheckpointsincancerimmunotherapy
AT yangangang diversityofimmunecheckpointsincancerimmunotherapy
AT zhengguoxu diversityofimmunecheckpointsincancerimmunotherapy